Abstract Session
Vasculitis
Peter Merkel, MD,MPH
University of Pennsylvania
Philadelphia, Pennsylvania, United States
No financial relationships with ineligible companies to disclose
Across nearly all evaluated subgroups in SELECT-GCA, treatment with UPA15 resulted in generally similar rates of sustained remission and sustained complete remission as observed for the overall trial population. These results further support the efficacy of UPA15 across the population of patients with GCA.
References
1. Blockmans D, et al. Ann Rheum Dis. 2024;83(1):232.
P. Merkel: AbbVie/Abbot, 2, AstraZeneca, 2, Boehringer Ingelheim, 2, GlaxoSmithKlein(GSK), 2, Roche, 5; A. Setty: AbbVie, 3, 11; R. Blanco-Alonso: AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Galapagos, 6, Janssen, 2, 6, Lilly, 2, 6, MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6; R. Suppiah: AbbVie, 2, 6, GlaxoSmithKline, 2, 6, Pfizer, 2, 6, Roche, 2, 6; T. Daikeler: None; V. Devauchelle: AbbVie, 2, BMS, 2, 5, Chugai, 5, Galapagos, 2, Janssen, 2, Lilly, 2, 5, Novartis, 2, Pfizer, 2; E. Brouwer: Auto-immune Research Hub (ARCH), 4, UMCG, 12, as an employee of the UMCG, received grants from the Dutch Arthritis Society (DAS) and the EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertakin; H. Tamaki: AbbVie, 6, Asahi Kasei Pharma, 6, Astellas Pharma, 6, AstraZeneca, 6, Ayumi, 6, Dai-ichi-Sankyo, 6, Eisai, 6, Eisai Chugai Pharmaceutical, 6, GSK, 6, Kissei Pharmaceutical, 6, Kyowa-Kirin, 6, Lilly, 6, Ono Pharmaceutical, 6, Pfizer, 6, Sanofi, 6, Takeda Pharmaceutical, 6, Tanabe-Mitsubishi, 6; L. Meng: AbbVie, 3, 11; Y. Yang: AbbVie, 3, 11; A. Joshi: AbbVie, 3, 11; C. Phillips: AbbVie, 3, 11; P. Wung: AbbVie, 3, 11; C. Ponte: AbbVie, 2, 5, AstraZeneca, 2, 5, CSL Vifor, 2, 5, GSK, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, 5.